Fig. 3From: Effects of intravitreal injection of ranibizumab and aflibercept for branch retinal vein occlusion on the choroid: a retrospective study Change in SFCT in the IVR and IVA groups. There was no significant change in SFCT at 12 months post-treatment in the IVR group or in the IVA group (p = 0.37). SFCT, subfoveal choroidal thickness; IVR, intravitreal injection of ranibizumab; IVA, intravitreal injection of afliberceptBack to article page